These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 21925954)
1. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Peeters M; Cohn A; Köhne CH; Douillard JY Clin Colorectal Cancer; 2012 Mar; 11(1):14-23. PubMed ID: 21925954 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462 [TBL] [Abstract][Full Text] [Related]
3. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297 [TBL] [Abstract][Full Text] [Related]
7. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
10. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tian Y; Sidhu R Ann Oncol; 2014 Jan; 25(1):107-16. PubMed ID: 24356622 [TBL] [Abstract][Full Text] [Related]
11. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966 [TBL] [Abstract][Full Text] [Related]
12. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
13. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients]. Smith D; Bosacki C; Merrouche Y Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868 [TBL] [Abstract][Full Text] [Related]
14. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038 [TBL] [Abstract][Full Text] [Related]
15. Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC. Hebart H; Kiehl M; Tomasek J; Csoszi T; Koukakis R; Kafatos G; Kuhn A; Bjorklof K; Demonty G; Buchler T Adv Ther; 2019 Mar; 36(3):670-683. PubMed ID: 30689133 [TBL] [Abstract][Full Text] [Related]
16. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Graham CN; Hechmati G; Fakih MG; Knox HN; Maglinte GA; Hjelmgren J; Barber B; Schwartzberg LS J Med Econ; 2015; 18(8):619-28. PubMed ID: 25822327 [TBL] [Abstract][Full Text] [Related]
17. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Tebbutt N; Kotasek D; Burris HA; Schwartzberg LS; Hurwitz H; Stephenson J; Warner DJ; Chen L; Hsu CP; Goldstein D Cancer Chemother Pharmacol; 2015 May; 75(5):993-1004. PubMed ID: 25772756 [TBL] [Abstract][Full Text] [Related]
18. Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States. Gathirua-Mwangi WG; Sethi H; Afable MG; Bhattacharyya D; Khan T J Med Econ; 2021; 24(1):1164-1172. PubMed ID: 34529522 [TBL] [Abstract][Full Text] [Related]
19. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544 [TBL] [Abstract][Full Text] [Related]
20. Panitumumab: a review of its use in metastatic colorectal cancer. Keating GM Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]